Inmune Bio Inc.
INMB· Nasdaq
Released Mar 2, 2023, after the close
10-K filed Mar 2, 2023, 61 days after period end · 0001213900-23-016875
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $97.00K | $163.00K | — | — |
| Net Income | -$5.83M | -$9.67M | -$3.20M |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$2.32M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.